HALONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
HALOZYME THERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$122.50+0.66 (+0.54%)
Close on Oct 19, 2026
- Market cap
- $14.85B
- P/E (TTM)
- 36.1
- Dividend yield
- –
HALOZYME THERAPEUTICS, INC. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Royalties | $867.84M | $570.99M | $447.87M | $360.48M | $203.90M | $88.60M | $69.90M | $78.98M | $63.51M | – | 62.1% | +52.0% |
| Product sales, net | $376.44M | $303.49M | $300.85M | $191.03M | $104.22M | $55.99M | $66.05M | $28.23M | $50.40M | – | 27.0% | +24.0% |
| Proprietary product sales | $194.61M | $166.62M | $130.83M | $72.85M | $23.26M | $17.03M | – | – | – | – | 13.9% | +16.8% |
| Revenues under collaborative agreements | $152.33M | $140.84M | $80.53M | $108.61M | $135.19M | $123.01M | $60.05M | $44.65M | $202.71M | – | 10.9% | +8.2% |
| Bulk rHuPH20 sales | $133.02M | $86.33M | $115.44M | $82.08M | $80.96M | – | – | – | – | – | 9.5% | +54.1% |
| Sales-based milestones | $70.00M | $30.00M | $0 | $10.00M | $50.00M | $15.00M | $0 | $0 | $1.42M | – | 5.0% | +133.3% |
| Product sales to partners | $48.81M | $50.54M | $54.58M | $36.10M | $0 | $0 | – | – | – | – | 3.5% | -3.4% |
| Event-based development and regulatory milestones and other fees | $47.00M | $72.50M | $69.00M | $59.00M | $42.00M | – | – | – | – | – | 3.4% | -35.2% |
| Upfront license and target nomination fees | $18.47M | $27.00M | $2.00M | $30.00M | – | – | – | – | – | – | 1.3% | -31.6% |
| Device licensing and development revenue | $16.86M | $11.34M | $9.53M | $9.61M | – | – | – | – | – | – | 1.2% | +48.6% |
| Hylenex | – | – | – | – | $23.26M | $17.03M | $17.00M | $15.05M | $15.15M | $16.16M | – | – |
| Bulk rHuPH20 sales | – | – | – | $82.08M | $80.96M | $38.96M | $49.05M | $12.73M | $35.25M | $37.24M | – | – |
| ENHANZ Edrugproduct Member | – | – | – | – | – | $719.00K | $768.00K | $460.00K | $0 | $0 | – | – |
| Event-based development milestones and regulatory milestone and other fees | – | – | – | $59.00M | $42.00M | $69.50M | $5.50M | $16.00M | $16.32M | – | – | – |
| Device licensing and development revenue | – | – | $9.53M | $9.61M | $1.19M | $1.25M | $1.55M | $2.31M | $12.17M | – | – | – |
| Upfront license and target nomination fees | – | – | $2.00M | $30.00M | $42.00M | $37.26M | $53.00M | $26.34M | $172.81M | – | – | – |
By region
From the segment and revenue-disaggregation notes of Halozyme Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.